Abstract
Primary or secondary resistance towards conventional chemotherapeutic agents presents the major clinical obstacle in the induction of remission and definite cure of hematological malignancies. Definition of the underlying molecular mechanisms determining response or resistance not only enables the clinician to define prognostic markers, but moreover, facilitates the design of molecularly targeted therapies aiming to reverse the causative lesion and/or the therapeutic resistance. Prostate-apoptosis-response-gene-4 (par-4), which is expressed in a broad spectrum of normal and neoplastic tissues, was originally described in prostate cancer cells forced to undergo apoptosis. In particular, the observation that overexpression of par-4 potentiates apoptosis in malignant cells while sparing normal tissues, renders the assessment of its biological properties and their potential therapeutic exploitation worthwhile. This article focuses on the functional properties of par- 4 in hematopoietic cells, describing their pro-apoptotic and anti-transforming role, and provides an outlook on the potential therapeutical employment of this knowledge.
Keywords: par, chemoresistance, hematopoiesis
Letters in Drug Design & Discovery
Title: Prostate-Apoptosis-Response-Gene-4: Biological Properties and their Potential Therapeutic Exploitation in Hematological Malignancies
Volume: 2 Issue: 4
Author(s): Simone Boehrer, Daniel Nowak, Dieter Hoelzer, Paris S. Mitrou and Kai Uwe Chow
Affiliation:
Keywords: par, chemoresistance, hematopoiesis
Abstract: Primary or secondary resistance towards conventional chemotherapeutic agents presents the major clinical obstacle in the induction of remission and definite cure of hematological malignancies. Definition of the underlying molecular mechanisms determining response or resistance not only enables the clinician to define prognostic markers, but moreover, facilitates the design of molecularly targeted therapies aiming to reverse the causative lesion and/or the therapeutic resistance. Prostate-apoptosis-response-gene-4 (par-4), which is expressed in a broad spectrum of normal and neoplastic tissues, was originally described in prostate cancer cells forced to undergo apoptosis. In particular, the observation that overexpression of par-4 potentiates apoptosis in malignant cells while sparing normal tissues, renders the assessment of its biological properties and their potential therapeutic exploitation worthwhile. This article focuses on the functional properties of par- 4 in hematopoietic cells, describing their pro-apoptotic and anti-transforming role, and provides an outlook on the potential therapeutical employment of this knowledge.
Export Options
About this article
Cite this article as:
Boehrer Simone, Nowak Daniel, Hoelzer Dieter, Mitrou S. Paris and Chow Uwe Kai, Prostate-Apoptosis-Response-Gene-4: Biological Properties and their Potential Therapeutic Exploitation in Hematological Malignancies, Letters in Drug Design & Discovery 2005; 2 (4) . https://dx.doi.org/10.2174/1570180054038350
DOI https://dx.doi.org/10.2174/1570180054038350 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Review of <i>Aristolochia indica</i>: Ethnomedicinal Uses, Phytochemistry, Pharmacological and Toxicological Effects
Current Traditional Medicine Targeting the Acute Myeloid Leukemia Stem Cells
Anti-Cancer Agents in Medicinal Chemistry An Update on the Xenograft and Mouse Models Suitable for Investigating New Therapeutic Compounds for the Treatment of B-Cell Malignancies
Current Pharmaceutical Design Cancer Pharmacogenomics: Germline DNA, Tumor DNA, or Both?
Current Pharmacogenomics Skin Cancers in Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry Protein Geranylgeranyltransferase Type 1 as a Target in Cancer
Current Cancer Drug Targets Forodesine (BCX-1777, Immucillin H) - A New Purine Nucleoside Analogue: Mechanism of Action and Potential Clinical Application
Mini-Reviews in Medicinal Chemistry The Role of Fibroblast Growth Factors in Tumor Growth
Current Cancer Drug Targets Targeting MDM2 and MDMX in Retinoblastoma
Current Cancer Drug Targets Endothelial and Circulating Progenitor Cells in Hematological Diseases and Allogeneic Hematopoietic Stem Cell Transplantation
Current Medicinal Chemistry Hemopoiesis in Ph-Negative Chronic Myeloproliferative Disorders
Current Stem Cell Research & Therapy Tumor-Targeting Peptides and Small Molecules as Anti-Cancer Agents to Overcome Drug Resistance
Current Medicinal Chemistry New Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia
Current Pharmaceutical Biotechnology Second Generation Abl Kinase Inhibitors and Novel Compounds to Eliminate the Bcr-Abl/T315I Clone
Recent Patents on Anti-Cancer Drug Discovery The Role of Apoptosis in Cancer Development and Treatment: Focusing on the Development and Treatment of Hematologic Malignancies
Current Pharmaceutical Design Stroke in Women - Oral Contraception, Pregnancy, and Hormone Replacement Therapy
Current Vascular Pharmacology Pharmacodynamics and Pharmacokinetics of Antifungals for Treatment of Invasive Aspergillosis
Current Pharmaceutical Design Immunotherapy of Human Cancers Using Gene Modified T Lymphocytes
Current Gene Therapy Focal Adhesion Kinase as a Therapeutic Target of Bortezomib
Anti-Cancer Agents in Medicinal Chemistry Reactive Oxygen Species in Cancer Biology and Anticancer Therapy
Current Medicinal Chemistry